Anbio Biotechnology (NNNN)
Nasdaq: NNNN · In Vitro & In Vivo Diagnostic Substances · Frankfurt Am Main, DE · filing with the SEC since 2023
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Apr 7, 2026 | Apr 28, 2025 | · | · |
| Revenue | 8,646,844 | 8,185,146 | 6,711,990 | 23,544,652 |
| Cost of revenue | 1,103,682 | 2,299,762 | 3,351,121 | 10,980,847 |
| Gross profit | 7,543,162 | 5,885,384 | 3,360,869 | 12,563,805 |
| Research and development | 201,305 | 454,227 | 134,700 | 200,000 |
| Selling, general and administrative | 1,574,117 | 3,435,790 | 1,265,240 | 2,168,217 |
| Total operating expenses | 1,775,422 | 3,890,017 | 1,399,940 | 2,368,217 |
| Operating income | 5,767,740 | 1,995,367 | 1,960,929 | 10,195,588 |
| Interest expense | · | · | · | 7,999 |
| Interest and investment income | 142,023 | 337,511 | 165,336 | 42,245 |
| Total non-operating income (expense) | 635,723 | 377,475 | 292,780 | -184,411 |
| Income before income taxes | 6,403,463 | 2,372,842 | 2,253,709 | 10,011,177 |
| Income tax expense | 0 | 0 | 0 | · |
| Net income | 6,403,463 | 2,372,842 | 2,253,709 | 10,011,177 |
| Earnings per share, basic | 0.147 | 0.056 | 0.105 | 100,112.00 |
| Earnings per share, diluted | 0.147 | 0.056 | 0.105 | 100,112.00 |
| Weighted average shares, basic | 43,672,022 | 42,291,200r | 21,435,315r | 100 |
| Weighted average shares, diluted | 43,672,022 | 42,291,200 | 21,435,315 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding